-
Je něco špatně v tomto záznamu ?
Soluble endoglin as a biomarker of successful rheopheresis treatment in patients with age-related macular degeneration
V. Blaha, JU. Rathouska, H. Langrova, M. Blaha, J. Studnicka, C. Andrys, V. Loefflerova, M. Lanska, E. Vejrazkova, P. Nachtigal, A. Stepanov
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
Grantová podpora
17-29241A
Ministerstvo Zdravotnictví Ceské Republiky
CZ.02.01.01/00/22_008/0004607
European Union
NLK
Directory of Open Access Journals
od 2011
Free Medical Journals
od 2011
Nature Open Access
od 2011-12-01
PubMed Central
od 2011
Europe PubMed Central
od 2011
ProQuest Central
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Health & Medicine (ProQuest)
od 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2011
- MeSH
- biologické markery * krev MeSH
- endoglin * krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- makulární degenerace * terapie krev MeSH
- senioři MeSH
- výsledek terapie MeSH
- zraková ostrost MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
Age-related macular degeneration (AMD) is a progressive chronic disease causing visual impairment or central vision loss in the elderly. We hypothesized that successful rheopheresis would be associated with positive changes in soluble endoglin (sENG), PSCK9, alpha-2-macroglobulin (A2M), and hs-CRP levels. 31 elderly patients with the dry form of AMD, treated with rheopheresis with a follow-up period of at least 5 years and an average age of 68 ± 4 years, were evaluated. Each treated patient received a series of 8 procedures in 10 weeks and, after the 2-year period, another 2 procedures within 1 week. Then, the patients were followed up every 6 months and divided into the successfully treated and therapeutic failure group according to best-corrected visual acuity (BCVA), size of the drusen area, and the drusenoid pigment epithelium detachment (DPED). Based on the ophthalmological assessment, rheopheresis treatment was successful in 73% of AMD patients. The therapy was associated with a significant decrease in total cholesterol, LDL-C, HDL-C, apoprotein B, lipoprotein (a) levels, and rheologically important parameters, irrespective of the therapy's success or failure. The success of rheopheresis therapy was exclusively related to a significant decrease in sENG and A2M levels. Over the long term, rheopheresis prevented the decline of BCVA, reduced the DPED and area of macular drusen, and improved the preservation of an intact photoreceptor ellipsoid zone in most patients. Moreover, we showed for the first time that sENG and A2M could be potentially sensitive biomarkers of successful rheopheresis procedure, irrespective of lipid parameters changes.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25003416
- 003
- CZ-PrNML
- 005
- 20250206104330.0
- 007
- ta
- 008
- 250121s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41598-024-80375-5 $2 doi
- 035 __
- $a (PubMed)39572693
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Blaha, Vladimir $u Faculty of Medicine in Hradec Kralove, 3rd Department of Internal Medicine - Metabolism and Gerontology, University Hospital Hradec Kralove and Charles University, Hradec Kralove, Czech Republic
- 245 10
- $a Soluble endoglin as a biomarker of successful rheopheresis treatment in patients with age-related macular degeneration / $c V. Blaha, JU. Rathouska, H. Langrova, M. Blaha, J. Studnicka, C. Andrys, V. Loefflerova, M. Lanska, E. Vejrazkova, P. Nachtigal, A. Stepanov
- 520 9_
- $a Age-related macular degeneration (AMD) is a progressive chronic disease causing visual impairment or central vision loss in the elderly. We hypothesized that successful rheopheresis would be associated with positive changes in soluble endoglin (sENG), PSCK9, alpha-2-macroglobulin (A2M), and hs-CRP levels. 31 elderly patients with the dry form of AMD, treated with rheopheresis with a follow-up period of at least 5 years and an average age of 68 ± 4 years, were evaluated. Each treated patient received a series of 8 procedures in 10 weeks and, after the 2-year period, another 2 procedures within 1 week. Then, the patients were followed up every 6 months and divided into the successfully treated and therapeutic failure group according to best-corrected visual acuity (BCVA), size of the drusen area, and the drusenoid pigment epithelium detachment (DPED). Based on the ophthalmological assessment, rheopheresis treatment was successful in 73% of AMD patients. The therapy was associated with a significant decrease in total cholesterol, LDL-C, HDL-C, apoprotein B, lipoprotein (a) levels, and rheologically important parameters, irrespective of the therapy's success or failure. The success of rheopheresis therapy was exclusively related to a significant decrease in sENG and A2M levels. Over the long term, rheopheresis prevented the decline of BCVA, reduced the DPED and area of macular drusen, and improved the preservation of an intact photoreceptor ellipsoid zone in most patients. Moreover, we showed for the first time that sENG and A2M could be potentially sensitive biomarkers of successful rheopheresis procedure, irrespective of lipid parameters changes.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a biologické markery $x krev $7 D015415
- 650 12
- $a makulární degenerace $x terapie $x krev $7 D008268
- 650 12
- $a endoglin $x krev $7 D000071063
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a zraková ostrost $7 D014792
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Rathouska, Jana Urbankova $u Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Heyrovskeho 1203, 500 05, Hradec Kralove, Czech Republic
- 700 1_
- $a Langrova, Hana $u Faculty of Medicine in Hradec Kralove, Department of Ophthalmology, University Hospital Hradec Kralove and Charles University, Hradec Kralove, Czech Republic
- 700 1_
- $a Blaha, Milan $u Faculty of Medicine in Hradec Kralove, 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove and Charles University, Hradec Kralove, Czech Republic
- 700 1_
- $a Studnicka, Jan $u Faculty of Medicine in Hradec Kralove, Department of Ophthalmology, University Hospital Hradec Kralove and Charles University, Hradec Kralove, Czech Republic
- 700 1_
- $a Andrys, Ctirad $u Department of Immunology and Allergology, Faculty of Medicine in Hradec Kralove, University Hospital Hradec Kralove and Charles University, Hradec Kralove, Czech Republic
- 700 1_
- $a Loefflerova, Veronika $u Department of Ophthalmology, Regional Hospital Liberec, Liberec, Czech Republic
- 700 1_
- $a Lanska, Miriam $u Faculty of Medicine in Hradec Kralove, 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove and Charles University, Hradec Kralove, Czech Republic
- 700 1_
- $a Vejrazkova, Eva $u Faculty of Medicine in Hradec Kralove, 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove and Charles University, Hradec Kralove, Czech Republic
- 700 1_
- $a Nachtigal, Petr $u Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Heyrovskeho 1203, 500 05, Hradec Kralove, Czech Republic. petr.nachtigal@faf.cuni.cz
- 700 1_
- $a Stepanov, Alexandr $u Faculty of Medicine in Hradec Kralove, Department of Ophthalmology, University Hospital Hradec Kralove and Charles University, Hradec Kralove, Czech Republic
- 773 0_
- $w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 14, č. 1 (2024), s. 28902
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39572693 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206104325 $b ABA008
- 999 __
- $a ok $b bmc $g 2263286 $s 1239423
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 14 $c 1 $d 28902 $e 20241121 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
- GRA __
- $a 17-29241A $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a CZ.02.01.01/00/22_008/0004607 $p European Union
- LZP __
- $a Pubmed-20250121